EverHint – Momentum Swing — Aggressive Momentum for Apr 13, 2026 – 2 Signals – Technology Leads (1)

2 signals. Technology leads (1). 2 with insider selling. price range $63-$128. sectors: Technology (1), Healthcare (1). full analyst coverage, earnings data.

What This Signal Is (Quick)

Aggressive Momentum is a momentum swing trading strategy focused on Triple threat: high momentum + high volume + high volatility.

Signal Type: Breakout (momentum continuation)

What Makes This Signal:

  • Stock showing strong momentum near or at highs
  • Increased volume confirms institutional interest
  • Breaking out or consolidating near resistance
  • Triple threat: high momentum + high volume + high volatility

Ideal For: Aggressive traders seeking maximum momentum with high risk/reward

Key Criteria:

  • Strong RSI momentum (configurable thresholds)

  • Volume surge above average

  • Price momentum confirmation

  • Minimum ADV: $25M+ (varies by variant)

  • Earnings buffer: 7 days pre/post earnings

  • Variant-specific filters applied

Holding Period: 1-4 weeks
Risk Level: Medium-High


How We Ranked Today

Ranked by composite momentum score (higher = stronger momentum)


📊 Momentum Swing — Aggressive Momentum Signals (2 Total)

Ranked by score:

Rank Ticker Company Sector Last ($) Score Vol Thrust @52w Insider Net Days → Earnings Est EPS Mkt Cap ($B)
1 FORM FormFactor, Inc. Technology 128.22 0.300 2.73x 0.0% $-472K 15 $0.00 10.0
2 SYRE Spyre Therapeutics, Inc. Healthcare 63.27 0.000 5.21x 0.0% $-1.5M 23 $-3.74 3.8

Field Notes

Sector concentration: Technology (1), Healthcare (1)

Insider selling: SYRE (Spyre Therapeutics, Inc., $-1.5M), FORM (FormFactor, Inc., $-472K)

Data coverage: 100.0% insider, 0.0% congressional, 100.0% earnings, 100.0% analyst, 0.0% news


Peer Analysis

Understanding how these stocks relate to their industry peers:

FORM (FormFactor, Inc.): Leads 10 peers: SLAB ($211.32, +0.1%), AMBA ($54.30, +2.9%), IPGP ($127.32), SIMO ($126.00, -0.6%), VICR ($186.22, +0.3%) | Peer of: ALGM ($38.04, +1.4%), AMBA ($54.30, +2.9%), AVGO ($379.75, +2.2%) and 4 more

SYRE (Spyre Therapeutics, Inc.): Leads 10 peers: PHVS ($27.88, +4.7%), IMNM ($22.62, +4.3%), WVE ($7.26, +1.1%), NTLA ($14.26, +5.7%), ZYME ($26.17, -0.6%) | Peer of: ABCL ($3.66, +3.4%), ARDX ($6.33, +2.4%), AZTA ($23.33, +5.0%) and 12 more


Market Context

Broad market indices advanced today, with the Nasdaq leading gains at +1.23%, followed by the S&P 500 at +1.01% and the Dow Jones at +0.62%. This upward trend signals strong risk appetite among investors, creating a favorable environment for aggressive momentum swing strategies that capitalize on short-term directional moves. The VIX declining 1.04% to 19.03 indicates moderating volatility, which tempers extreme intraday swings but still supports momentum plays by reducing whipsaw risks while preserving enough movement for profitable entries and exits.

Lower volatility levels enhance the reliability of momentum signals in this context, as smoother price action allows aggressive strategies to ride established trends without excessive noise. With major indices posting solid gains, the prevailing bullish bias aligns well with momentum swing approaches, encouraging traders to lean into upside breakouts amid heightened risk-on sentiment. However, the modest VIX elevation suggests monitoring for any spikes that could amplify swings and increase stop-loss triggers.

Technology as the top-performing sector reinforces sector rotation toward growth-oriented areas, amplifying momentum opportunities within this aggressive framework. The Nasdaq's outperformance underscores capital flowing into high-beta sectors, ideal for swing trades seeking quick reversals or continuations. Traders should prioritize signals in leading sectors to leverage this rotation, while broader market strength provides tailwinds for total signal deployment.

Sharing Call-to-Action

✅ If this added value to your research, consider liking, sharing, or subscribing. It genuinely helps.


Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.

This is not financial advice. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/